Sinovac Biotech ( (SVA) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sinovac Biotech Ltd. has filed a Form 12b-25 to notify investors that it will not meet the deadline for its Annual Report on Form 20-F (Yearly Report) for the year ended December 31, 2025. The delay relates directly to a major legal and auditing disruption that has forced the company to revisit several prior years of financial reporting.
In January 2025, the Judicial Committee of the Privy Council of the United Kingdom issued a ruling concerning Sinovac, triggering significant knock-on effects. By April 15, 2025, its then-auditor Grant Thornton Zhitong Certified Public Accountants LLP resigned and simultaneously advised that its audit opinions for 2021, 2022, and 2023 should no longer be relied upon.
Following this, Sinovac appointed Zhonghua Certified Public Accountants LLP on December 31, 2025 to take over as independent auditor. Zhonghua has been engaged to perform integrated audits for 2025 and 2024 and financial statement audits for 2023, 2022, and 2021, reflecting the depth of the restatement work now required.
The company has concluded that both its common and preferred shares need retrospective adjustment in light of the Privy Council ruling. As a result, its consolidated financial statements for 2021 through 2023 must be restated, which is the central reason for the late filing of the 2025 Form 20-F (Yearly Report).
Sinovac has indicated, under the relief provided by Form 12b-25, that it expects to submit the delayed annual report within the 15-day grace period following the original deadline. Management states that the 2025 Annual Report will be filed as soon as practicable once the new auditor completes the necessary audit and restatement procedures.
The company acknowledged that it has already experienced prior delays, including the 2024 Form 20-F (Yearly Report), which was only filed on April 30, 2026 due to the same underlying issues. However, Sinovac does not currently anticipate any significant change in its results of operations versus the prior year based on information expected to appear in the upcoming 2025 filing.
Investors should note that any expectations regarding timing, restatement impacts, and audit completion are inherently forward-looking and subject to change. While the company has not provided preliminary financial figures, the extensive audit and restatement process could affect investor sentiment until the updated annual reports are available.
Sinovac emphasizes that it is working to complete the integrated audits and restatements to return to a normal reporting schedule. The notification was signed on April 30, 2026 by Chief Financial Officer Nan Wang, signaling executive-level oversight of the compliance effort and the company’s intention to resolve its reporting delays.
Spark’s Take on SVA Stock
According to Spark, TipRanks’ AI Analyst, SVA is a Neutral.
Sinovac Biotech’s overall score reflects its strong liquidity and balance sheet, offset by poor financial performance and lack of earnings. The technical indicators suggest neutrality, and the valuation appears unattractive due to the negative P/E ratio.
To see Spark’s full report on SVA stock, click here.
More about Sinovac Biotech
Sinovac Biotech Ltd. is a China-based biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines. Its products target infectious diseases, and the company is known globally for its role in vaccine supply from its base in Beijing’s Haidian District.
Average Trading Volume: 8,227
Technical Sentiment Signal: Hold
Current Market Cap: $460.3M
For an in-depth examination of SVA stock, go to TipRanks’ Overview page.